How much revenue does Shine-On BioMedical make?

Shine-On BioMedical reported 30.00 million TWD in revenue for fiscal year 2025.

What companies are similar to Shine-On BioMedical?

Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Taho Pharma (6467.TWO), PharmaEngine, Inc. (4162.TWO), Acepodia, Inc. (6976.TWO), InnoPharmax Inc. (4172.TWO).

Shine-On BioMedical Co.,Ltd. (6926.TWO) Stock

About Shine-On BioMedical Co.,Ltd.

Shine-On BioMedical Co.,Ltd. research, develops, and manufactures anti-cancer related drug products. It also develops antibody anticancer drugs, such as exosome anti-cancer drugs, that includes SOB101 and SOB102; SOB201 for engineered multi-target exosomes; SOA101, a dual immune checkpoint T cell adapter antibody; and SOA201, a trispecific adapter immune cell antibody. Shine-On BioMedical Co.,Ltd....

At a glance

Shine-On BioMedical reported revenue of 30.00 million TWD for fiscal year 2025, and net income of -110.29 million TWD.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.